{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T09:55:16Z","timestamp":1719827716956},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,7]]},"DOI":"10.7759\/cureus.59781","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T09:03:56Z","timestamp":1715072636000},"source":"Crossref","is-referenced-by-count":1,"title":["Multiple Myeloma: A Personal Account of My Journey With the Disease and Response to Teclistamab"],"prefix":"10.7759","author":[{"given":"Mohammad","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Musa F","family":"Zahrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghazi  S","family":"Alotaibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatimah","family":"Alshalati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ammarah","family":"Afzal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim N","family":"Alrumaih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rabia","family":"Riaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Tayyab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo A","year":"2011","unstructured":"Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011, 364:1046-60. 10.1056\/NEJMra1011442","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0003","article-title":"iagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan AJ","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, et al.. iagnosis and management of multiple myeloma: a review. JAMA. 2022, 327:464-77. 10.1001\/jama.2022.0003","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-05058-5","article-title":"The emerging therapeutic landscape of relapsed\/refractory multiple myeloma","volume":"102","author":"Tanenbaum B","year":"2023","unstructured":"Tanenbaum B, Miett T, Patel SA. The emerging therapeutic landscape of relapsed\/refractory multiple myeloma. Ann Hematol. 2023, 102:1-11. 10.1007\/s00277-022-05058-5","journal-title":"Ann Hematol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11122015","article-title":"Pursuing a curative approach in multiple myeloma: a review of new therapeutic strategies","volume":"11","author":"D'Agostino M","year":"2019","unstructured":"D'Agostino M, Bertamini L, Oliva S, Boccadoro M, Gay F. Pursuing a curative approach in multiple myeloma: a review of new therapeutic strategies. Cancers (Basel). 2019, 11:38. 10.3390\/cancers11122015","journal-title":"Cancers (Basel)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar SV","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, et al.. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014, 15:538-48. 10.1016\/S1470-2045(14)70442-5","journal-title":"Lancet Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar SV","year":"2022","unstructured":"Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022, 97:1086-107. 10.1002\/ajh.26590","journal-title":"Am J Hematol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar SK","year":"2014","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, et al.. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014, 28:1122-8. 10.1038\/leu.2013.313","journal-title":"Leukemia"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2817","article-title":"Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma","volume":"106","author":"Rajkumar SV","year":"2005","unstructured":"Rajkumar SV, Hayman SR, Lacy MQ, et al.. Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma. Blood. 2005, 106:4050-3. 10.1182\/blood-2005-07-2817","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-015909","article-title":"A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma","volume":"108","author":"Richardson PG","year":"2006","unstructured":"Richardson PG, Blood E, Mitsiades CS, et al.. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006, 108:3458-64. 10.1182\/blood-2006-04-015909","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC- 1): a multicenter, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani SZ","year":"2021","unstructured":"Usmani SZ, Garfall AL, van de Donk N, et al.. Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC- 1): a multicenter, open-label, single-arm, phase 1 study. Lancet. 2021, 398:665-74. 10.1016\/S0140-6736(21)01338-6","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01793-1","article-title":"Teclistamab: first approval","volume":"82","author":"Kang C","year":"2022","unstructured":"Kang C. Teclistamab: first approval. Drugs. 2022, 82:1613-9. 10.1007\/s40265-022-01793-1","journal-title":"Drugs"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/life13122259","article-title":"Progression-free survival efficacy in refractory\/relapsed multiple myeloma among elderly patients: a systematic review","volume":"13","author":"Yang TL","year":"2023","unstructured":"Yang TL, Lin C, Ho CL, et al.. Progression-free survival efficacy in refractory\/relapsed multiple myeloma among elderly patients: a systematic review. Life (Basel). 2023, 13:2259. 10.3390\/life13122259","journal-title":"Life (Basel)"},{"key":"ref13","unstructured":"Mayoclinic. (2024). Accessed. February 24, 2024: https:\/\/www.mayoclinic.org\/drugs-supplements\/teclistamab-cqyv-subcutaneous-route\/side-effects\/drg-20545969."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35107","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC\u20101study","volume":"130","author":"Nooka AK","year":"2024","unstructured":"Nooka AK, Rodriguez C, Mateos MV, et al.. Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC\u20101study. Cancer. 2024, 130:886-900. 10.1002\/cncr.35107","journal-title":"Cancer"},{"key":"ref15","unstructured":"TECVAYLI\u00ae (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma. (2024). Accessed. March 12, 2024: https:\/\/www.prnewswire.com\/news-releases\/tecvayli-teclistamab-cqyv-biweekly-dosing-approved-by-the-us-fda-for-the-tre...."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau P","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NW, et al.. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022, 387:495-505. 10.1056\/NEJMoa2203478","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01003-z","article-title":"Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study","volume":"14","author":"Mohan M","year":"2024","unstructured":"Mohan M, Monge J, Shah N, et al.. Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood Cancer J. 2024, 14:35. 10.1038\/s41408-024-01003-z","journal-title":"Blood Cancer J"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-024-01818-6","article-title":"Targeted immunotherapy: harnessing the immune system to battle multiple myeloma","volume":"10","author":"Xu L","year":"2024","unstructured":"Xu L, Wen C, Xia J, Zhang H, Liang Y, Xu X. Targeted immunotherapy: harnessing the immune system to battle multiple myeloma. Cell Death Discov. 2024, 10:55. 10.1038\/s41420-024-01818-6","journal-title":"Cell Death Discov"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S372237","article-title":"Teclistamab for multiple myeloma: clinical insights and practical considerations for a first-in-class bispecific antibody","volume":"15","author":"Pan D","year":"2023","unstructured":"Pan D, Richter J. Teclistamab for multiple myeloma: clinical insights and practical considerations for a first-in-class bispecific antibody. Cancer Manag Res. 2023, 15:741-51. 10.2147\/CMAR.S372237","journal-title":"Cancer Manag Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.12.016","article-title":"Safety and efficacy of teclistamab in patients with elapsed\/refractory multiple myeloma: a real-world experience","volume":"30","author":"Dima D","year":"2024","unstructured":"Dima D, Davis JA, Ahmed N, et al.. Safety and efficacy of teclistamab in patients with elapsed\/refractory multiple myeloma: a real-world experience. Transplant Cell Ther. 2024, 30:308.e1-308.e13. 10.1016\/j.jtct.2023.12.016","journal-title":"Transplant Cell Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/252179-multiple-myeloma-a-personal-account-of-my-journey-with-the-disease-and-response-to-teclistamab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T09:04:00Z","timestamp":1715072640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/252179-multiple-myeloma-a-personal-account-of-my-journey-with-the-disease-and-response-to-teclistamab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,7]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.59781","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,7]]}}}